VIP Research Study
A multicenter, randomized, double blind placebo controlled trial assessing the effect of adalimumab (Humira), when compared to NB-UVB phototherapy or placebo injection. The study will compare the effects of each on systemic inflammation and cardiovascular disease risk factors in subjects diagnosed with moderate to severe psoriasis.
- Must be 18 years of age or older
- Have had a diagnosis of psoriasis for at least 6 months
- Moderate to severe plaque type psoriasis with ≥10% body surface area
Study-related visits, medications, and tests will be provided to you at no cost if you qualify. You will be compensated for time and travel.
Contact: Dr. Michael Caglia, 801-213-2629